Upgrade to SI Premium - Free Trial

Camp4 Therapeutics gets UK approval for SYNGAP1 drug trial

September 10, 2026 7:33 AM
Camp4 Therapeutics Corporation (Nasdaq: CAMP) has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA